Monica F. Chen

Phase II Trial of First-line Axitinib plus Nivolumab in Patients with Advanced Mucosal Melanoma

Sarah E. Lochrin, Hannah L. Kalvin, Monica F. Chen, James W. Smithy et autres

us (code pays fourni par la source)

PTCH1 mutations and tumor-agnostic clinical outcomes with hedgehog pathway inhibitors across cancer types

Antoine Desîlets, Matteo Repetto, Sen Yang, Monica F. Chen et autres

us (code pays fourni par la source)

The Genomic Landscape of MYC -, MYCL -, and MYCN -Amplified Solid Tumors

Matteo Repetto, Allison L. Richards, Monica F. Chen, Pier Selenica et autres

us (code pays fourni par la source)

Supplementary Table 22 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada et autres

Supplementary Table 18 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada et autres

Supplementary Table 11 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada et autres

Supplementary Figure 10 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada et autres

Supplementary Table 19 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada et autres

Supplementary Figure 20 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada et autres

Supplementary Figure 5 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada et autres

Supplementary Table 8 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada et autres

Supplementary Table 6 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada et autres